InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
71.25
(
0.50%
)
Bitcoin
90,828.25
(
-0.25%
)
Post# of 253625
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120734
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 228290

Tuesday, 01/21/2020 5:32:35 PM

Tuesday, January 21, 2020 5:32:35 PM

Post# of 253625
Re: VIR HBV program

From your post:

The company anticipates that two new trials with VIR-2218 will start later this year, including a Phase 2 trial of VIR-2218 in China, in collaboration with Brii Biosciences, and a Phase 2 combination trial of VIR-2218 and pegylated interferon-alpha.

It’s been a long time since I’ve seen a new trial that tests combination therapy with peg-ifn. Such a regimen might make sense in certain emerging markets, but I doubt that it will be an enterprising proposition for the US, EU, or Japan.

p.s. ENTA plans to report phase-1 top-line data in HBV during the current quarter.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up